AbbVie Inc. (ABBV) FY2024 Annual P&L / Income Statement

AbbVie Inc. (ABBV) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

56,334,000,000 US dollars

Cost of products sold

16,904,000,000 US dollars

Gross profit (calculated)

39,430,000,000 US dollars

Operating expenses (calculated)

30,293,000,000 US dollars

Operating earnings

9,137,000,000 US dollars

Other income (expense), net (calculated)

negative 5,421,000,000 US dollars

Earnings before income tax expense

3,716,000,000 US dollars

Income tax expense (benefit)

negative 570,000,000 US dollars

Net earnings

4,286,000,000 US dollars

UNITED STATES

43,029,000,000 US dollars

GERMANY

1,465,000,000 US dollars

CANADA

1,088,000,000 US dollars

JAPAN

1,122,000,000 US dollars

CHINA

917,000,000 US dollars

FRANCE

776,000,000 US dollars

AUSTRALIA

463,000,000 US dollars

SPAIN

528,000,000 US dollars

UNITED KINGDOM

522,000,000 US dollars

ITALY

511,000,000 US dollars

BRAZIL

464,000,000 US dollars

All other countries

5,449,000,000 US dollars

Selling, general and administrative

14,752,000,000 US dollars

Research and development

12,791,000,000 US dollars

Acquired IPR&D and milestones

2,757,000,000 US dollars

Other operating expense (income), net

negative 7,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $4.28 B; to noncontrolling interests: $8.00 M.